Sinocare Inc (300298) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocare Inc (300298) has a cash flow conversion efficiency ratio of 0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥264.19 Million ≈ $38.66 Million USD) by net assets (CN¥3.67 Billion ≈ $537.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinocare Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Sinocare Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Sinocare Inc for a breakdown of total debt and financial obligations.
Sinocare Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocare Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
0.037x |
|
Zhejiang Wanliyang Transmission Co Ltd
SHE:002434
|
0.065x |
|
Kennedy-Wilson Holdings Inc
NYSE:KW
|
-0.005x |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
N/A |
|
PharmaBlock Sciences Nanjing Inc Class A
SHE:300725
|
0.012x |
|
Bell AG
SW:BELL
|
0.170x |
|
American Axle & Manufacturing
NYSE:AXL
|
0.188x |
|
Dalata Hotel Group Plc
IR:DHG
|
0.022x |
Annual Cash Flow Conversion Efficiency for Sinocare Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Sinocare Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see 300298 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.77 Billion ≈ $551.61 Million |
CN¥631.29 Million ≈ $92.38 Million |
0.167x | -20.94% |
| 2023-12-31 | CN¥3.47 Billion ≈ $507.88 Million |
CN¥735.15 Million ≈ $107.57 Million |
0.212x | +40.36% |
| 2022-12-31 | CN¥3.14 Billion ≈ $460.00 Million |
CN¥474.39 Million ≈ $69.42 Million |
0.151x | -12.21% |
| 2021-12-31 | CN¥2.79 Billion ≈ $408.61 Million |
CN¥480.03 Million ≈ $70.24 Million |
0.172x | -6.63% |
| 2020-12-31 | CN¥2.74 Billion ≈ $401.11 Million |
CN¥504.64 Million ≈ $73.84 Million |
0.184x | -6.72% |
| 2019-12-31 | CN¥2.65 Billion ≈ $387.62 Million |
CN¥522.81 Million ≈ $76.50 Million |
0.197x | +62.15% |
| 2018-12-31 | CN¥2.62 Billion ≈ $383.83 Million |
CN¥319.27 Million ≈ $46.72 Million |
0.122x | -30.65% |
| 2017-12-31 | CN¥1.39 Billion ≈ $203.34 Million |
CN¥243.89 Million ≈ $35.69 Million |
0.176x | +10.25% |
| 2016-12-31 | CN¥1.28 Billion ≈ $186.99 Million |
CN¥203.42 Million ≈ $29.77 Million |
0.159x | +62.46% |
| 2015-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
CN¥121.52 Million ≈ $17.78 Million |
0.098x | -28.90% |
| 2014-12-31 | CN¥1.11 Billion ≈ $162.61 Million |
CN¥153.15 Million ≈ $22.41 Million |
0.138x | +13.95% |
| 2013-12-31 | CN¥946.01 Million ≈ $138.43 Million |
CN¥114.42 Million ≈ $16.74 Million |
0.121x | -20.83% |
| 2012-12-31 | CN¥845.18 Million ≈ $123.68 Million |
CN¥129.12 Million ≈ $18.89 Million |
0.153x | -68.09% |
| 2011-12-31 | CN¥179.51 Million ≈ $26.27 Million |
CN¥85.93 Million ≈ $12.57 Million |
0.479x | -34.81% |
| 2010-12-31 | CN¥91.35 Million ≈ $13.37 Million |
CN¥67.08 Million ≈ $9.82 Million |
0.734x | -29.18% |
| 2009-12-31 | CN¥41.49 Million ≈ $6.07 Million |
CN¥43.03 Million ≈ $6.30 Million |
1.037x | +136.80% |
| 2008-12-31 | CN¥17.42 Million ≈ $2.55 Million |
CN¥7.63 Million ≈ $1.12 Million |
0.438x | -- |
About Sinocare Inc
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People's Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic disease… Read more